Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Signed and dated informed consent form,~* End-stage renal disease,~* Candidates for a first transplantation,~* Re-transplant patients are eligible if a graft loss after transplantation was NOT due to immunological reasons,~* Availability of a heart-beating cadaveric donor up to 70 years of age with a cold ischemia time shorter than 36 hours,~* Male or female patients between 18 to 75 years of age inclusive,~* Patients able to comply with all study related requirements,~* Patients able to receive oral medication,~* Women of childbearing age with a safe contraceptive method throughout the study.~Exclusion Criteria~* Women who are pregnant or breast feeding,~* Known Human Immunodeficiency Virus,~* Hepatitis B Virus or Hepatitis C Virus infection,~* Severe actual viral, bacterial or fungal infection not adequately controlled,~* Patients with anamnestically known hypersensitivity to rabbit immunoglobulin antibodies or positive rabbit immunoglobulin skin test or known allergies to any component of the immunosuppressive drugs per protocol,~* Patients at high immunological risk defined as current PRA \> 25% or historical PRA \> 50%,~* Patients receiving pre-transplant immunosuppressive treatment, including corticosteroids,~* Patients with current or history of malignancies (exception basal cell carcinoma or squamous cell carcinoma in remission),~* Patients with previous transplantation except 1st graft loss due to surgical complications,~* Patients receiving combined transplantation,~* Patients with major organ dysfunctions,~* Serious psychiatric or psychological disorders,~* Pre-transplant thrombocytopenia: \< 50,000 thrombocytes/µl, Pre-transplant leukopenia: \< 2,000 leukocytes/µl,~* Unable or unwilling to comply fully with the protocol,~* Participation in another study of an investigational medicinal product concurrently or within the last 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: ACTIVE_COMPARATOR): immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
- Control Group (Type: NO_INTERVENTION): immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).